FSP Senior Medical Writer
Thermo Fisher ScientificFull Time
Senior (5 to 8 years)
Candidates must possess a minimum of a Bachelor's degree in Life Sciences or a related discipline, with an advanced degree being preferred. A solid understanding of biochemistry and molecular biology principles is required, along with a minimum of 5 years of experience writing clinical and regulatory documents for a pharmaceutical or biotechnology company. Proficiency in writing, editing, and reviewing protocols, clinical study reports, investigator brochures, CTD modules, and other clinical regulatory documents per guidelines is essential. Knowledge of FDA/international regulations, ICH guidelines, and applicable US/international regulatory processes is necessary. Candidates should be proficient with Microsoft Office, Adobe Acrobat, and shared document systems like SharePoint and Veeva. The ability to work independently, prioritize tasks, problem-solve, complete high-quality documents under aggressive timelines, and a commitment to accuracy and detail are also required.
The Associate Director, Medical Writing is responsible for the timely preparation of high-quality, compliant clinical and regulatory documents for one or more clinical programs. This includes writing, editing, and collaborating on protocols, investigator brochures, clinical study reports, CTDs, and briefing books. The role involves reviewing and ensuring the quality of documents prepared by others, overseeing document review comment resolution meetings, and contributing to project management and cross-functional working groups to facilitate document development. Additionally, the position supports the development of best practices for authoring and reviewing, focusing on continuous process improvement.
Develops AI-optimized gene therapy vectors
Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.